ID   PAK1_HUMAN              Reviewed;         545 AA.
AC   Q13153; O75561; Q13567; Q32M53; Q32M54; Q86W79;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   22-JUL-2015, entry version 176.
DE   RecName: Full=Serine/threonine-protein kinase PAK 1;
DE            EC=2.7.11.1;
DE   AltName: Full=Alpha-PAK;
DE   AltName: Full=p21-activated kinase 1;
DE            Short=PAK-1;
DE   AltName: Full=p65-PAK;
GN   Name=PAK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=8805275; DOI=10.1016/S0960-9822(02)00546-8;
RA   Brown J.L., Stowers L., Baer M., Trejo J., Coughlin S., Chant J.;
RT   "Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase
RT   pathway.";
RL   Curr. Biol. 6:598-605(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=9395435; DOI=10.1016/S0960-9822(97)70091-5;
RA   Sells M.A., Knaus U.G., Bagrodia S., Ambrose D.M., Bokoch G.M.,
RA   Chernoff J.;
RT   "Human p21-activated kinase (Pak1) regulates actin organization in
RT   mammalian cells.";
RL   Curr. Biol. 7:202-210(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Reid T., Aspenstroem P., Bertoglio J.;
RT   "Human PAK1B.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, ENZYME REGULATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=9032240;
RA   Manser E., Huang H.Y., Loo T.H., Chen X.Q., Dong J.M., Leung T.,
RA   Lim L.;
RT   "Expression of constitutively active alpha-PAK reveals effects of the
RT   kinase on actin and focal complexes.";
RL   Mol. Cell. Biol. 17:1129-1143(1997).
RN   [7]
RP   MUTAGENESIS OF HIS-83 AND HIS-86.
RX   PubMed=9774440; DOI=10.1074/jbc.273.43.28191;
RA   Frost J.A., Khokhlatchev A., Stippec S., White M.A., Cobb M.H.;
RT   "Differential effects of PAK1-activating mutations reveal activity-
RT   dependent and -independent effects on cytoskeletal regulation.";
RL   J. Biol. Chem. 273:28191-28198(1998).
RN   [8]
RP   FUNCTION, AND AUTOREGULATORY DOMAIN.
RX   PubMed=9528787;
RA   Zhao Z.S., Manser E., Chen X.Q., Chong C., Leung T., Lim L.;
RT   "A conserved negative regulatory region in alphaPAK: inhibition of PAK
RT   kinases reveals their morphological roles downstream of Cdc42 and
RT   Rac1.";
RL   Mol. Cell. Biol. 18:2153-2163(1998).
RN   [9]
RP   INTERACTION WITH NCK1 AND NCK2.
RX   PubMed=10026169; DOI=10.1074/jbc.274.9.5542;
RA   Braverman L.E., Quilliam L.A.;
RT   "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-
RT   containing adapter protein having similar binding and biological
RT   properties to Nck.";
RL   J. Biol. Chem. 274:5542-5549(1999).
RN   [10]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AUTOREGULATORY REGION,
RP   FUNCTION, INTERACTION WITH CDC42, PHOSPHORYLATION AT THR-423, AND
RP   MUTAGENESIS OF HIS-83; HIS-86; LEU-107 AND THR-423.
RX   PubMed=10551809; DOI=10.1074/jbc.274.46.32565;
RA   Zenke F.T., King C.C., Bohl B.P., Bokoch G.M.;
RT   "Identification of a central phosphorylation site in p21-activated
RT   kinase regulating autoinhibition and kinase activity.";
RL   J. Biol. Chem. 274:32565-32573(1999).
RN   [11]
RP   PHOSPHORYLATION AT THR-423 BY PDPK1, INTERACTION WITH PDPK1, AND
RP   ENZYME REGULATION.
RX   PubMed=10995762; DOI=10.1074/jbc.M006553200;
RA   King C.C., Gardiner E.M., Zenke F.T., Bohl B.P., Newton A.C.,
RA   Hemmings B.A., Bokoch G.M.;
RT   "p21-activated kinase (PAK1) is phosphorylated and activated by 3-
RT   phosphoinositide-dependent kinase-1 (PDK1).";
RL   J. Biol. Chem. 275:41201-41209(2000).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RAF1, AND INTERACTION WITH RAF1.
RX   PubMed=11733498; DOI=10.1074/jbc.M110000200;
RA   Zang M., Hayne C., Luo Z.;
RT   "Interaction between active Pak1 and Raf-1 is necessary for
RT   phosphorylation and activation of Raf-1.";
RL   J. Biol. Chem. 277:4395-4405(2002).
RN   [13]
RP   SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=11804587; DOI=10.1016/S1097-2765(01)00428-2;
RA   Parrini M.C., Lei M., Harrison S.C., Mayer B.J.;
RT   "Pak1 kinase homodimers are autoinhibited in trans and dissociated
RT   upon activation by Cdc42 and Rac1.";
RL   Mol. Cell 9:73-83(2002).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH CDC2L1 AND CDC2L2.
RX   PubMed=12624090; DOI=10.1074/jbc.M300818200;
RA   Chen S., Yin X., Zhu X., Yan J., Ji S., Chen C., Cai M., Zhang S.,
RA   Zong H., Hu Y., Yuan Z., Shen Z., Gu J.;
RT   "The C-terminal kinase domain of the p34cdc2-related PITSLRE protein
RT   kinase (p110C) associates with p21-activated kinase 1 and inhibits its
RT   activity during anoikis.";
RL   J. Biol. Chem. 278:20029-20036(2003).
RN   [15]
RP   FUNCTION.
RX   PubMed=12876277; DOI=10.1083/jcb.200212141;
RA   Slack-Davis J.K., Eblen S.T., Zecevic M., Boerner S.A.,
RA   Tarcsafalvi A., Diaz H.B., Marshall M.S., Weber M.J., Parsons J.T.,
RA   Catling A.D.;
RT   "PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK
RT   activation.";
RL   J. Cell Biol. 162:281-291(2003).
RN   [16]
RP   PHOSPHORYLATION AT SER-21, IDENTIFICATION BY MASS SPECTROMETRY,
RP   FUNCTION, INTERACTION WITH NCK1, AND SUBCELLULAR LOCATION.
RX   PubMed=14585966; DOI=10.1128/MCB.23.22.8058-8069.2003;
RA   Zhou G.L., Zhuo Y., King C.C., Fryer B.H., Bokoch G.M., Field J.;
RT   "Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and
RT   cell migration.";
RL   Mol. Cell. Biol. 23:8058-8069(2003).
RN   [17]
RP   INTERACTION WITH DSCAM.
RX   PubMed=15169762; DOI=10.1074/jbc.M401878200;
RA   Li W., Guan K.L.;
RT   "The Down syndrome cell adhesion molecule (DSCAM) interacts with and
RT   activates Pak.";
RL   J. Biol. Chem. 279:32824-32831(2004).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=15833848; DOI=10.1158/0008-5472.CAN-05-0236;
RA   Yang Z., Rayala S., Nguyen D., Vadlamudi R.K., Chen S., Kumar R.;
RT   "Pak1 phosphorylation of snail, a master regulator of epithelial-to-
RT   mesenchyme transition, modulates snail's subcellular localization and
RT   functions.";
RL   Cancer Res. 65:3179-3184(2005).
RN   [19]
RP   FUNCTION.
RX   PubMed=15611088; DOI=10.1074/jbc.M411900200;
RA   Zhou H., Kramer R.H.;
RT   "Integrin engagement differentially modulates epithelial cell motility
RT   by RhoA/ROCK and PAK1.";
RL   J. Biol. Chem. 280:10624-10635(2005).
RN   [20]
RP   INTERACTION WITH CIB1, AND SUBCELLULAR LOCATION.
RX   PubMed=16061695; DOI=10.1083/jcb.200502090;
RA   Leisner T.M., Liu M., Jaffer Z.M., Chernoff J., Parise L.V.;
RT   "Essential role of CIB1 in regulating PAK1 activation and cell
RT   migration.";
RL   J. Cell Biol. 170:465-476(2005).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH TBCB.
RX   PubMed=15831477; DOI=10.1128/MCB.25.9.3726-3736.2005;
RA   Vadlamudi R.K., Barnes C.J., Rayala S., Li F., Balasenthil S.,
RA   Marcus S., Goodson H.V., Sahin A.A., Kumar R.;
RT   "p21-activated kinase 1 regulates microtubule dynamics by
RT   phosphorylating tubulin cofactor B.";
RL   Mol. Cell. Biol. 25:3726-3736(2005).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-212, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH CRIPAK.
RX   PubMed=16278681; DOI=10.1038/sj.onc.1209172;
RA   Talukder A.H., Meng Q., Kumar R.;
RT   "CRIPak, a novel endogenous Pak1 inhibitor.";
RL   Oncogene 25:1311-1319(2006).
RN   [24]
RP   FUNCTION, PHOSPHORYLATION AT TYR-153; TYR-201 AND TYR-285, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17726028; DOI=10.1074/jbc.M701794200;
RA   Rider L., Shatrova A., Feener E.P., Webb L., Diakonova M.;
RT   "JAK2 tyrosine kinase phosphorylates PAK1 and regulates PAK1 activity
RT   and functions.";
RL   J. Biol. Chem. 282:30985-30996(2007).
RN   [25]
RP   FUNCTION, PHOSPHORYLATION AT SER-21; SER-57; TYR-131; TYR-142;
RP   TYR-153; SER-174; THR-185; THR-212 AND TYR-285, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=17989089; DOI=10.1242/jcs.008177;
RA   Mayhew M.W., Jeffery E.D., Sherman N.E., Nelson K., Polefrone J.M.,
RA   Pratt S.J., Shabanowitz J., Parsons J.T., Fox J.W., Hunt D.F.,
RA   Horwitz A.F.;
RT   "Identification of phosphorylation sites in betaPIX and PAK1.";
RL   J. Cell Sci. 120:3911-3918(2007).
RN   [26]
RP   INTERACTION WITH RAC1 AND CDC42.
RX   PubMed=18325335; DOI=10.1016/j.febslet.2008.01.064;
RA   Matsuda C., Kameyama K., Suzuki A., Mishima W., Yamaji S., Okamoto H.,
RA   Nishino I., Hayashi Y.K.;
RT   "Affixin activates Rac1 via betaPIX in C2C12 myoblast.";
RL   FEBS Lett. 582:1189-1196(2008).
RN   [27]
RP   INTERACTION WITH SCRIB.
RX   PubMed=18716323; DOI=10.1093/hmg/ddn248;
RA   Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S.,
RA   Navarro C., Rachel R., Montcouquiol M., Sans N.,
RA   Etienne-Manneville S., Borg J.-P., Santoni M.-J.;
RT   "Scrib regulates PAK activity during the cell migration process.";
RL   Hum. Mol. Genet. 17:3552-3565(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-230, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-204; THR-212; THR-219;
RP   SER-220 AND THR-230, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-144; SER-149; SER-174;
RP   SER-223 AND THR-230, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [33]
RP   FUNCTION, INTERACTION WITH BRSK2, AND PHOSPHORYLATION AT THR-423.
RX   PubMed=22669945; DOI=10.1074/jbc.M112.378372;
RA   Nie J., Sun C., Faruque O., Ye G., Li J., Liang Q., Chang Z., Yang W.,
RA   Han X., Shi Y.;
RT   "Synapses of amphids defective (SAD-A) kinase promotes glucose-
RT   stimulated insulin secretion through activation of p21-activated
RT   kinase (PAK1) in pancreatic beta-Cells.";
RL   J. Biol. Chem. 287:26435-26444(2012).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-115, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [36]
RP   INTERACTION WITH CIB1 ISOFORM 2.
RC   TISSUE=Brain;
RX   PubMed=23503467; DOI=10.1038/onc.2013.43;
RA   Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V.,
RA   Vandoninck S., Van Lint J., Illing A., Seufferlein T.;
RT   "A novel splice variant of calcium and integrin-binding protein 1
RT   mediates protein kinase D2-stimulated tumour growth by regulating
RT   angiogenesis.";
RL   Oncogene 33:1167-1180(2014).
RN   [37]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=23633677; DOI=10.1126/scisignal.2003627;
RA   Borroni E.M., Cancellieri C., Vacchini A., Benureau Y., Lagane B.,
RA   Bachelerie F., Arenzana-Seisdedos F., Mizuno K., Mantovani A.,
RA   Bonecchi R., Locati M.;
RT   "Beta-arrestin-dependent activation of the cofilin pathway is required
RT   for the scavenging activity of the atypical chemokine receptor D6.";
RL   Sci. Signal. 6:RA30-RA30(2013).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 70-545.
RX   PubMed=10975528; DOI=10.1016/S0092-8674(00)00043-X;
RA   Lei M., Lu W., Meng W., Parrini M.C., Eck M.J., Mayer B.J.,
RA   Harrison S.C.;
RT   "Structure of PAK1 in an autoinhibited conformation reveals a
RT   multistage activation switch.";
RL   Cell 102:387-397(2000).
RN   [39]
RP   STRUCTURE BY NMR OF 183-204 IN COMPLEX WITH ARHGEF7, AND INTERACTION
RP   WITH ARHGEF7.
RX   PubMed=16101281; DOI=10.1021/bi050374a;
RA   Mott H.R., Nietlispach D., Evetts K.A., Owen D.;
RT   "Structural analysis of the SH3 domain of beta-PIX and its interaction
RT   with alpha-p21 activated kinase (PAK).";
RL   Biochemistry 44:10977-10983(2005).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 249-545, AND ENZYME
RP   REGULATION.
RX   PubMed=15893667; DOI=10.1016/j.str.2005.03.007;
RA   Lei M., Robinson M.A., Harrison S.C.;
RT   "The active conformation of the PAK1 kinase domain.";
RL   Structure 13:769-778(2005).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 248-545 OF MUTANT ARG-299 IN
RP   COMPLEX WITH ATP ANALOG AMP-PNP, MUTAGENESIS OF LYS-299 AND ASP-389,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBUNIT, AND PHOSPHORYLATION
RP   AT THR-423.
RX   PubMed=22153498; DOI=10.1016/j.str.2011.10.013;
RA   Wang J., Wu J.W., Wang Z.X.;
RT   "Structural insights into the autoactivation mechanism of p21-
RT   activated protein kinase.";
RL   Structure 19:1752-1761(2011).
CC   -!- FUNCTION: Protein kinase involved in intracellular signaling
CC       pathways downstream of integrins and receptor-type kinases that
CC       plays an important role in cytoskeleton dynamics, in cell
CC       adhesion, migration, proliferation, apoptosis, mitosis, and in
CC       vesicle-mediated transport processes. Can directly phosphorylate
CC       BAD and protects cells against apoptosis. Activated by interaction
CC       with CDC42 and RAC1. Functions as GTPase effector that links the
CC       Rho-related GTPases CDC42 and RAC1 to the JNK MAP kinase pathway.
CC       Phosphorylates and activates MAP2K1, and thereby mediates
CC       activation of downstream MAP kinases. Involved in the
CC       reorganization of the actin cytoskeleton, actin stress fibers and
CC       of focal adhesion complexes. Phosphorylates the tubulin chaperone
CC       TBCB and thereby plays a role in the regulation of microtubule
CC       biogenesis and organization of the tubulin cytoskeleton. Plays a
CC       role in the regulation of insulin secretion in response to
CC       elevated glucose levels. Part of a ternary complex that contains
CC       PAK1, DVL1 and MUSK that is important for MUSK-dependent
CC       regulation of AChR clustering during the formation of the
CC       neuromuscular junction (NMJ). Activity is inhibited in cells
CC       undergoing apoptosis, potentially due to binding of CDC2L1 and
CC       CDC2L2. Phosphorylates MYL9/MLC2. Phosphorylates RAF1 at 'Ser-338'
CC       and 'Ser-339' resulting in: activation of RAF1, stimulation of
CC       RAF1 translocation to mitochondria, phosphorylation of BAD by
CC       RAF1, and RAF1 binding to BCL2. Phosphorylates SNAI1 at 'Ser-246'
CC       promoting its transcriptional repressor activity by increasing its
CC       accumulation in the nucleus. In podocytes, promotes NR3C2 nuclear
CC       localization. Required for atypical chemokine receptor ACKR2-
CC       induced phosphorylation of LIMK1 and cofilin (CFL1) and for the
CC       up-regulation of ACKR2 from endosomal compartment to cell
CC       membrane, increasing its efficiency in chemokine uptake and
CC       degradation. In synapses, seems to mediate the regulation of F-
CC       actin cluster formation performed by SHANK3, maybe through CFL1
CC       phosphorylation and inactivation. {ECO:0000269|PubMed:10551809,
CC       ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:12624090,
CC       ECO:0000269|PubMed:12876277, ECO:0000269|PubMed:14585966,
CC       ECO:0000269|PubMed:15611088, ECO:0000269|PubMed:15831477,
CC       ECO:0000269|PubMed:15833848, ECO:0000269|PubMed:16278681,
CC       ECO:0000269|PubMed:17726028, ECO:0000269|PubMed:17989089,
CC       ECO:0000269|PubMed:22669945, ECO:0000269|PubMed:23633677,
CC       ECO:0000269|PubMed:8805275, ECO:0000269|PubMed:9032240,
CC       ECO:0000269|PubMed:9395435, ECO:0000269|PubMed:9528787}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:22153498,
CC       ECO:0000269|PubMed:9032240}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Phosphorylation of Thr-84 by OXSR1 inhibits
CC       activation (By similarity). Activated by binding small G proteins.
CC       Binding of GTP-bound CDC42 or RAC1 to the autoregulatory region
CC       releases monomers from the autoinhibited dimer, and enables
CC       activation by phosphorylation of Thr-423. {ECO:0000250,
CC       ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:11804587,
CC       ECO:0000269|PubMed:15893667, ECO:0000269|PubMed:9032240}.
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer.
CC       Component of cytoplasmic complexes, which also contains PXN,
CC       ARHGEF6 and GIT1. Interacts with NISCH (By similarity). Interacts
CC       with DVL1; mediates the formation of a DVL1, MUSK and PAK1 ternary
CC       complex involved in AChR clustering (By similarity). Binds to the
CC       caspase-cleaved p110 isoform of CDC2L1 and CDC2L2, p110C, but not
CC       the full-length proteins. Interacts with ARHGEF7. Interacts
CC       tightly with GTP-bound but not GDP-bound CDC42/P21 and RAC1.
CC       Probably found in a ternary complex composed of DSCAM, PAK1 and
CC       RAC1. Interacts with DSCAM (via cytoplasmic domain); the
CC       interaction is direct and enhanced in presence of RAC1. Interacts
CC       with SCRIB. Interacts with PDPK1. Interacts (via kinase domain)
CC       with RAF1. Interacts with NCK1 and NCK2. Interacts with TBCB.
CC       Interacts with CRIPAK. Interacts with BRSK2. Interacts with SNAI1.
CC       Interacts with CIB1 isoform 2. Interacts with CIB1 (via N-terminal
CC       region); the interaction is direct, promotes PAK1 activity and
CC       occurs in a calcium-dependent manner. {ECO:0000250,
CC       ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:10551809,
CC       ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:11733498,
CC       ECO:0000269|PubMed:11804587, ECO:0000269|PubMed:12624090,
CC       ECO:0000269|PubMed:14585966, ECO:0000269|PubMed:15169762,
CC       ECO:0000269|PubMed:15831477, ECO:0000269|PubMed:15833848,
CC       ECO:0000269|PubMed:16061695, ECO:0000269|PubMed:16101281,
CC       ECO:0000269|PubMed:16278681, ECO:0000269|PubMed:18325335,
CC       ECO:0000269|PubMed:18716323, ECO:0000269|PubMed:22153498,
CC       ECO:0000269|PubMed:22669945, ECO:0000269|PubMed:23503467}.
CC   -!- INTERACTION:
CC       Q14155:ARHGEF7; NbExp=7; IntAct=EBI-1307, EBI-717515;
CC       P60953:CDC42; NbExp=7; IntAct=EBI-1307, EBI-81752;
CC       P60766:Cdc42 (xeno); NbExp=3; IntAct=EBI-1307, EBI-81763;
CC       P21127:CDK11B; NbExp=4; IntAct=EBI-1307, EBI-1298;
CC       Q8N1N5:CRIPAK; NbExp=6; IntAct=EBI-1307, EBI-1205846;
CC       Q9Y2X7:GIT1; NbExp=3; IntAct=EBI-1307, EBI-466061;
CC       P53667:LIMK1; NbExp=5; IntAct=EBI-1307, EBI-444403;
CC       O43639:NCK2; NbExp=4; IntAct=EBI-1307, EBI-713635;
CC       P63000:RAC1; NbExp=19; IntAct=EBI-1307, EBI-413628;
CC       P63001:Rac1 (xeno); NbExp=3; IntAct=EBI-1307, EBI-413646;
CC       Q7L0Q8:RHOU; NbExp=2; IntAct=EBI-1019502, EBI-1638043;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell junction, focal adhesion.
CC       Cell membrane. Cell projection, ruffle membrane. Note=Recruited to
CC       the cell membrane by interaction with CDC42 and RAC1. Recruited to
CC       focal adhesions upon activation. Colocalized with CIB1 within
CC       membrane ruffles during cell spreading upon readhesion to
CC       fibronectin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13153-1; Sequence=Displayed;
CC       Name=2; Synonyms=PAK1B;
CC         IsoId=Q13153-2; Sequence=VSP_017507;
CC   -!- PTM: Autophosphorylated in trans, meaning that in a dimer, one
CC       kinase molecule phosphorylates the other one. Activated by
CC       autophosphorylation at Thr-423 in response to a conformation
CC       change, triggered by interaction with GTP-bound CDC42 or RAC1.
CC       Activated by phosphorylation at Thr-423 by BRSK2 and by PDPK1.
CC       Phosphorylated by JAK2 in response to PRL; this increases PAK1
CC       kinase activity. Phosphorylated at Ser-21 by PKB/AKT; this reduces
CC       interaction with NCK1 and association with focal adhesion sites.
CC       {ECO:0000269|PubMed:10551809, ECO:0000269|PubMed:10995762,
CC       ECO:0000269|PubMed:14585966, ECO:0000269|PubMed:17726028,
CC       ECO:0000269|PubMed:17989089, ECO:0000269|PubMed:22153498,
CC       ECO:0000269|PubMed:22669945, ECO:0000269|PubMed:23633677}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 CRIB domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00057}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAK1ID41633ch11q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U51120; AAC50590.1; -; mRNA.
DR   EMBL; U24152; AAA65441.1; -; mRNA.
DR   EMBL; AF071884; AAC24716.1; -; mRNA.
DR   EMBL; AP000486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC109299; AAI09300.1; -; mRNA.
DR   CCDS; CCDS44687.1; -. [Q13153-2]
DR   CCDS; CCDS8250.1; -. [Q13153-1]
DR   PIR; G01773; G01773.
DR   RefSeq; NP_001122092.1; NM_001128620.1. [Q13153-2]
DR   RefSeq; NP_002567.3; NM_002576.4. [Q13153-1]
DR   RefSeq; XP_011543382.1; XM_011545080.1. [Q13153-2]
DR   RefSeq; XP_011543383.1; XM_011545081.1. [Q13153-2]
DR   RefSeq; XP_011543384.1; XM_011545082.1. [Q13153-2]
DR   RefSeq; XP_011543385.1; XM_011545083.1. [Q13153-2]
DR   RefSeq; XP_011543386.1; XM_011545084.1. [Q13153-2]
DR   UniGene; Hs.435714; -.
DR   PDB; 1F3M; X-ray; 2.30 A; A/B=70-149, C/D=249-545.
DR   PDB; 1YHV; X-ray; 1.80 A; A=249-545.
DR   PDB; 1YHW; X-ray; 1.80 A; A=249-545.
DR   PDB; 1ZSG; NMR; -; B=183-204.
DR   PDB; 2HY8; X-ray; 2.00 A; 1=249-545.
DR   PDB; 2QME; X-ray; 1.75 A; I=74-109.
DR   PDB; 3DVP; X-ray; 2.50 A; C/D=212-221.
DR   PDB; 3FXZ; X-ray; 1.64 A; A=249-545.
DR   PDB; 3FY0; X-ray; 2.35 A; A=249-545.
DR   PDB; 3Q4Z; X-ray; 1.89 A; A/B=248-545.
DR   PDB; 3Q52; X-ray; 1.80 A; A=248-545.
DR   PDB; 3Q53; X-ray; 2.09 A; A=248-545.
DR   PDB; 4DAW; X-ray; 2.00 A; A=249-545.
DR   PDB; 4EQC; X-ray; 2.01 A; A=249-545.
DR   PDB; 4O0R; X-ray; 2.40 A; A/B=249-545.
DR   PDB; 4O0T; X-ray; 2.60 A; A/B=249-545.
DR   PDB; 4P90; X-ray; 2.49 A; A/B=249-545.
DR   PDBsum; 1F3M; -.
DR   PDBsum; 1YHV; -.
DR   PDBsum; 1YHW; -.
DR   PDBsum; 1ZSG; -.
DR   PDBsum; 2HY8; -.
DR   PDBsum; 2QME; -.
DR   PDBsum; 3DVP; -.
DR   PDBsum; 3FXZ; -.
DR   PDBsum; 3FY0; -.
DR   PDBsum; 3Q4Z; -.
DR   PDBsum; 3Q52; -.
DR   PDBsum; 3Q53; -.
DR   PDBsum; 4DAW; -.
DR   PDBsum; 4EQC; -.
DR   PDBsum; 4O0R; -.
DR   PDBsum; 4O0T; -.
DR   PDBsum; 4P90; -.
DR   ProteinModelPortal; Q13153; -.
DR   SMR; Q13153; 78-147, 188-541.
DR   BioGrid; 111095; 66.
DR   DIP; DIP-31016N; -.
DR   IntAct; Q13153; 48.
DR   MINT; MINT-92897; -.
DR   STRING; 9606.ENSP00000278568; -.
DR   BindingDB; Q13153; -.
DR   ChEMBL; CHEMBL4600; -.
DR   GuidetoPHARMACOLOGY; 2133; -.
DR   PhosphoSite; Q13153; -.
DR   BioMuta; PAK1; -.
DR   DMDM; 90111767; -.
DR   MaxQB; Q13153; -.
DR   PaxDb; Q13153; -.
DR   PRIDE; Q13153; -.
DR   DNASU; 5058; -.
DR   Ensembl; ENST00000278568; ENSP00000278568; ENSG00000149269. [Q13153-2]
DR   Ensembl; ENST00000356341; ENSP00000348696; ENSG00000149269.
DR   GeneID; 5058; -.
DR   KEGG; hsa:5058; -.
DR   UCSC; uc001oyg.4; human. [Q13153-2]
DR   UCSC; uc001oyh.4; human. [Q13153-1]
DR   CTD; 5058; -.
DR   GeneCards; GC11M077033; -.
DR   HGNC; HGNC:8590; PAK1.
DR   HPA; CAB005312; -.
DR   HPA; HPA003565; -.
DR   MIM; 602590; gene.
DR   neXtProt; NX_Q13153; -.
DR   PharmGKB; PA32917; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00800000124030; -.
DR   HOGENOM; HOG000234202; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q13153; -.
DR   KO; K04409; -.
DR   OMA; PTENNTP; -.
DR   OrthoDB; EOG7CK36J; -.
DR   PhylomeDB; Q13153; -.
DR   TreeFam; TF105351; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_12623; Generation of second messenger molecules.
DR   Reactome; REACT_160086; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; REACT_163701; FCERI mediated MAPK activation.
DR   Reactome; REACT_19226; Activation of Rac.
DR   Reactome; REACT_19236; Sema3A PAK dependent Axon repulsion.
DR   Reactome; REACT_19238; CD28 dependent Vav1 pathway.
DR   Reactome; REACT_22272; Signal transduction by L1.
DR   Reactome; REACT_25299; DSCAM interactions.
DR   Reactome; REACT_263952; EPHB-mediated forward signaling.
DR   Reactome; REACT_263991; VEGFR2 mediated vascular permeability.
DR   Reactome; REACT_264047; Ephrin signaling.
DR   Reactome; REACT_355347; RHO GTPases activate PAKs.
DR   Reactome; REACT_355503; CD209 (DC-SIGN) signaling.
DR   SignaLink; Q13153; -.
DR   ChiTaRS; PAK1; human.
DR   EvolutionaryTrace; Q13153; -.
DR   GeneWiki; PAK1; -.
DR   GenomeRNAi; 5058; -.
DR   NextBio; 19488; -.
DR   PRO; PR:Q13153; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; Q13153; -.
DR   CleanEx; HS_PAK1; -.
DR   ExpressionAtlas; Q13153; baseline and differential.
DR   Genevisible; Q13153; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:HGNC.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0014704; C:intercalated disc; ISS:UniProtKB.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IEA:Ensembl.
DR   GO; GO:0031965; C:nuclear membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030018; C:Z disc; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048365; F:Rac GTPase binding; IBA:GO_Central.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0016358; P:dendrite development; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006887; P:exocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0060244; P:negative regulation of cell proliferation involved in contact inhibition; IMP:UniProtKB.
DR   GO; GO:0007528; P:neuromuscular junction development; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043113; P:receptor clustering; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0007266; P:Rho protein signal transduction; IBA:GO_Central.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042060; P:wound healing; IMP:UniProtKB.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   Apoptosis; ATP-binding; Cell junction; Cell membrane; Cell projection;
KW   Complete proteome; Cytoplasm; Exocytosis; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:22814378}.
FT   CHAIN         2    545       Serine/threonine-protein kinase PAK 1.
FT                                /FTId=PRO_0000086460.
FT   DOMAIN       75     88       CRIB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00057}.
FT   DOMAIN      270    521       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     276    284       ATP.
FT   NP_BIND     345    347       ATP.
FT   REGION       70    140       Autoregulatory region.
FT   REGION       75    105       GTPase-binding.
FT   REGION      132    270       Interaction with CRIPAK.
FT   ACT_SITE    389    389       Proton acceptor.
FT   BINDING     299    299       ATP.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000269|PubMed:22814378}.
FT   MOD_RES      21     21       Phosphoserine; by PKB and autocatalysis.
FT                                {ECO:0000269|PubMed:14585966,
FT                                ECO:0000269|PubMed:17989089}.
FT   MOD_RES      57     57       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17989089}.
FT   MOD_RES      84     84       Phosphothreonine; by OXSR1.
FT                                {ECO:0000250}.
FT   MOD_RES     115    115       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES     131    131       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17989089}.
FT   MOD_RES     142    142       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:17989089}.
FT   MOD_RES     144    144       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   MOD_RES     149    149       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   MOD_RES     153    153       Phosphotyrosine; by JAK2.
FT                                {ECO:0000269|PubMed:17726028,
FT                                ECO:0000269|PubMed:17989089}.
FT   MOD_RES     174    174       Phosphoserine.
FT                                {ECO:0000269|PubMed:17989089,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     185    185       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17989089}.
FT   MOD_RES     199    199       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     201    201       Phosphotyrosine; by JAK2.
FT                                {ECO:0000269|PubMed:17726028}.
FT   MOD_RES     204    204       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     212    212       Phosphothreonine.
FT                                {ECO:0000269|PubMed:16964243,
FT                                ECO:0000269|PubMed:17989089,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     219    219       Phosphothreonine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     220    220       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     223    223       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   MOD_RES     230    230       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     285    285       Phosphotyrosine; by JAK2.
FT                                {ECO:0000269|PubMed:17726028,
FT                                ECO:0000269|PubMed:17989089}.
FT   MOD_RES     423    423       Phosphothreonine; by autocatalysis, BRSK2
FT                                and PDPK1. {ECO:0000269|PubMed:10551809,
FT                                ECO:0000269|PubMed:10995762,
FT                                ECO:0000269|PubMed:22153498,
FT                                ECO:0000269|PubMed:22669945}.
FT   VAR_SEQ     518    545       HQFLKIAKPLSSLTPLIAAAKEATKNNH -> VRKLRFQVF
FT                                SNFSMIAASIPEDCQAPLQPHSTDCCS (in isoform
FT                                2). {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_017507.
FT   VARIANT     515    515       L -> V (in dbSNP:rs35345144).
FT                                /FTId=VAR_051654.
FT   MUTAGEN      83     83       H->L: Abolishes interaction with CDC42,
FT                                leading to strongly decreased activity;
FT                                when associated with L-86.
FT                                {ECO:0000269|PubMed:10551809,
FT                                ECO:0000269|PubMed:9774440}.
FT   MUTAGEN      86     86       H->L: Abolishes interaction with CDC42,
FT                                leading to strongly decreased activity;
FT                                when associated with L-83.
FT                                {ECO:0000269|PubMed:10551809,
FT                                ECO:0000269|PubMed:9774440}.
FT   MUTAGEN     107    107       L->F: Abolishes autoinhibition, leading
FT                                to constitutive kinase activity.
FT                                {ECO:0000269|PubMed:10551809}.
FT   MUTAGEN     299    299       K->R: Strongly decreases activity.
FT                                Abolishes kinase activity; when
FT                                associated with N-389.
FT                                {ECO:0000269|PubMed:22153498}.
FT   MUTAGEN     389    389       D->N: Abolishes kinase activity; when
FT                                associated with R-299.
FT                                {ECO:0000269|PubMed:22153498}.
FT   MUTAGEN     393    393       D->A: Abolishes autophosphorylation at
FT                                Thr-423.
FT   MUTAGEN     423    423       T->A: Decreases CDC42-stimulated activity
FT                                and autophosphorylation.
FT                                {ECO:0000269|PubMed:10551809}.
FT   MUTAGEN     423    423       T->E: Constitutive kinase activity.
FT                                {ECO:0000269|PubMed:10551809}.
FT   CONFLICT     26     26       A -> V (in Ref. 2; AAA65441 and 3;
FT                                AAC24716). {ECO:0000305}.
FT   CONFLICT    237    237       R -> L (in Ref. 1; AAC50590).
FT                                {ECO:0000305}.
FT   CONFLICT    379    379       F -> S (in Ref. 1; AAC50590).
FT                                {ECO:0000305}.
FT   CONFLICT    503    503       E -> D (in Ref. 2; AAA65441).
FT                                {ECO:0000305}.
FT   STRAND       79     87       {ECO:0000244|PDB:2QME}.
FT   TURN         91     94       {ECO:0000244|PDB:2QME}.
FT   STRAND       95     98       {ECO:0000244|PDB:1F3M}.
FT   HELIX       101    108       {ECO:0000244|PDB:1F3M}.
FT   HELIX       114    119       {ECO:0000244|PDB:1F3M}.
FT   HELIX       121    135       {ECO:0000244|PDB:1F3M}.
FT   STRAND      195    198       {ECO:0000244|PDB:1ZSG}.
FT   STRAND      214    219       {ECO:0000244|PDB:3DVP}.
FT   HELIX       250    260       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      261    264       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       266    268       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      270    272       {ECO:0000244|PDB:3Q4Z}.
FT   STRAND      274    279       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      282    289       {ECO:0000244|PDB:3FXZ}.
FT   TURN        290    292       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      295    302       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       303    305       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       309    321       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      330    336       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      339    345       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      349    351       {ECO:0000244|PDB:1F3M}.
FT   HELIX       352    358       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       363    382       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       392    394       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      395    397       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      403    405       {ECO:0000244|PDB:3FXZ}.
FT   STRAND      408    410       {ECO:0000244|PDB:1F3M}.
FT   STRAND      416    418       {ECO:0000244|PDB:3Q52}.
FT   HELIX       428    430       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       433    437       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       444    459       {ECO:0000244|PDB:3FXZ}.
FT   TURN        463    466       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       469    479       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       487    489       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       492    501       {ECO:0000244|PDB:3FXZ}.
FT   TURN        506    508       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       512    515       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       519    523       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       527    530       {ECO:0000244|PDB:3FXZ}.
FT   HELIX       531    540       {ECO:0000244|PDB:3FXZ}.
SQ   SEQUENCE   545 AA;  60647 MW;  1A95CD5F2195CD7B CRC64;
     MSNNGLDIQD KPPAPPMRNT STMIGAGSKD AGTLNHGSKP LPPNPEEKKK KDRFYRSILP
     GDKTNKKKEK ERPEISLPSD FEHTIHVGFD AVTGEFTGMP EQWARLLQTS NITKSEQKKN
     PQAVLDVLEF YNSKKTSNSQ KYMSFTDKSA EDYNSSNALN VKAVSETPAV PPVSEDEDDD
     DDDATPPPVI APRPEHTKSV YTRSVIEPLP VTPTRDVATS PISPTENNTT PPDALTRNTE
     KQKKKPKMSD EEILEKLRSI VSVGDPKKKY TRFEKIGQGA SGTVYTAMDV ATGQEVAIKQ
     MNLQQQPKKE LIINEILVMR ENKNPNIVNY LDSYLVGDEL WVVMEYLAGG SLTDVVTETC
     MDEGQIAAVC RECLQALEFL HSNQVIHRDI KSDNILLGMD GSVKLTDFGF CAQITPEQSK
     RSTMVGTPYW MAPEVVTRKA YGPKVDIWSL GIMAIEMIEG EPPYLNENPL RALYLIATNG
     TPELQNPEKL SAIFRDFLNR CLEMDVEKRG SAKELLQHQF LKIAKPLSSL TPLIAAAKEA
     TKNNH
//
